Foghorn Therapeutics Inc.

For the period ended Jun 30, 2025. Filed Aug 5, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 5, 2025

FHTX$1.90-6.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Collaboration revenue	$7,557	$6,888	$13,509	$11,938
Operating expenses:
Research and development	21,792	23,797	43,418	49,331
General and administrative	6,862	7,325	14,101	15,035
Impairment of long-lived assets	—	2,398	—	2,398
Total operating expenses	28,654	33,520	57,519	66,764
Loss from operations	(21,097)	(26,632)	(44,010)	(54,826)
Other income, net:
Interest income	2,309	2,870	5,001	5,309
Other income, net	852	783	2,239	1,522
Total other income, net	3,161	3,653	7,240	6,831
Net loss	$(17,936)	$(22,979)	$(36,770)	$(47,995)
Net loss per share attributable to common stockholders—basic and diluted	$(0.28)	$(0.45)	$(0.58)	$(1.02)
Weighted average common shares outstanding—basic and diluted	62,978,219	51,580,310	62,913,804	47,004,561
Comprehensive loss:
Net loss	$(17,936)	$(22,979)	$(36,770)	$(47,995)
Other comprehensive gain (loss):
Unrealized gains (losses) on marketable securities	(58)	159	(179)	488
Total other comprehensive gain (loss)	(58)	159	(179)	488
Total comprehensive loss	$(17,994)	$(22,820)	$(36,949)	$(47,507)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.